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background:  Fractional flow reserve (FFR) is commonly used to assess the functional significance of intermediate coronary stenosis. 
Current guidelines recommend anticoagulation and dual anti-platelet (DAT) during elective percutaneous coronary interventions (PCI), but 
whether routine measurement of FFR requires anticoagulation and DAT is unclear. The goal of this study was to evaluate the safety of two 
simplified anti-thrombotic regimens during FFR calculation.
methods:  Three hundred patients undergoing elective coronary angiography, with a coronary stenosis of 50-70% by quantitative 
angiography in any major native epicardial coronary artery, were prospectively randomized in a double-blinded fashion into 3 groups. 
Group 1:DAT (Aspirin plus Clopidogrel), Group 2: DAT plus Bivalirudin, and Group 3:Aspirin plus Bivalirudin. All patients received a 
chewable aspirin of 325 mg and 600 mg of clopidogrel at least 6 hours before the procedure, according to randomization. Primary end-
points were the incidence of thrombotic complications whether procedural or during the hospital stay, and secondary end-points were TIMI 
major and minor bleeding scores, in-hospital myocardial infarction and death.
results:  Baseline demographic characteristics and medical therapy, except for anti-thrombotic therapy were comparable among groups. 
No statistical significant difference between the incidences of single, double and triple vessel disease by quantitative angiography was 
found. The vessel most frequently evaluated by FFR was the left anterior descending artery. There were no thrombotic complications in 
any group, and bailout thrombectomy or additional anti-thrombotic therapy was not required for any patient. TIMI major and minor bleeding 
scores were not significantly different among the three groups and no deaths or myocardial infarctions were reported.
Conclusion:  This pilot study suggests that measurements of FFR can be safely performed with simplified anti-thrombotic regimens 
including DAT without anticoagulation, and single anti-platelet therapy with aspirin, in addition to systemic anticoagulation, with similar 
results when compared with anticoagulation and DAT.
